Latest Breaking News On - Antonio lopez beltran - Page 1 : comparemela.com

Bladder cancer remains a leading cause of cancer death worldwide and is associated with substantial impacts on patient quality of life, morbidity, mortality, and cost to the healthcare system. Gross hematuria frequently precedes the diagnosis of bladder cancer. Non-muscle-invasive bladder cancer (NMIBC) is managed initially with transurethral resection of a bladder tumor (TURBT), followed by a risk stratified approach to adjuvant intravesical therapy (IVe), and is associated with an overall survival of 90%. However, cure rates remain lower for muscle invasive bladder cancer (MIBC) owing to a variety of factors. NMIBC and MIBC groupings are heterogeneous and have unique pathological and molecular characteristics. Indeed, The Cancer Genome Atlas project identified genetic drivers and luminal and basal molecular subtypes of MIBC with distinct treatment responses. For NMIBC, IVe immunotherapy (primarily BCG) is the gold standard treatment for high grade and high risk NMIBC to reduce or pre

France generalUnited statesLiang chengBrendanj guercioAntonio lopez beltranMichaels cooksonEuropean society for medical oncologyEastern cooperative oncology groupWorld health organizationDrug administrationEuropean association of urologyNational comprehensive cancer networkUnited states national comprehensive cancer networkCancer genome atlasEuropean societyMedical oncology